

# Association between the degree of fibrosis in fibrotic focus and the prognosis of breast cancer

Yongfu Li<sup>1</sup>, Yuhan Wei<sup>1</sup>, Wenjun Tang<sup>2</sup>, Jingru Luo<sup>2</sup>, Minghua Wang<sup>3</sup>, Haifeng Lin<sup>2</sup>, Hong Guo<sup>4</sup>, Yuling Ma<sup>5</sup>, Jun Zhang<sup>6</sup>, Qin Li<sup>Corresp. 1</sup>

<sup>1</sup> Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

<sup>2</sup> Department of Oncology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China

<sup>3</sup> Department of Pathology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, China

<sup>4</sup> Department of Surgery, Beijing Changping District Hospital of Traditional Medicine, Beijing, China

<sup>5</sup> Department of Gynecology, Beijing Changping District Hospital of Traditional Medicine, Beijing, China

<sup>6</sup> Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, US

Corresponding Author: Qin Li

Email address: oncologistinbj@163.com

**Objective.** To explore the association between the degree of fibrosis in fibrotic focus (FF) and the prognosis of breast cancer. **Methods.** 169 cases of breast invasive ductal carcinoma (IDC) were included in the study. Hematoxylin and eosin (H&E) staining was performed in the primary lesion of breast IDC and the degree of fibrosis in tumor-stromal FF was assessed. The association between the degree of fibrosis in FF and the well-known clinicopathologic features of breast cancer was investigated and the influence of the degree of fibrosis in FF on the survival was analyzed. **Results.** Tumor size > 2cm ( $P = 0.023$ ), vascular invasion ( $P = 0.011$ ), lymphatic vessel invasion ( $P < 0.001$ ) and HER-2+ ( $P = 0.032$ ) were positively correlated with the degree of fibrosis in FF in breast IDC. The result of multivariate analysis showed that lymphatic vessel invasion was the only independent correlation factor of high fibrosis in FF in breast IDC (OR = 3.82, 95% CI 1.13 ~12.82,  $P = 0.031$ ). The Nottingham prognostic index (NPI) of high fibrosis in FF was significantly higher than that of mild and moderate fibrosis in FF in the no vascular infiltration subgroup, the no nerve infiltration subgroup, and the Luminal A subgroup ( $P = 0.014$ , 0.039, and 0.018; respectively). **Conclusions.** The high fibrosis in FF is closely associated with the strong invasiveness and the high malignancy of breast IDC. The degree of fibrosis in FF might be considered as a very practical and meaningful pathological feature of breast cancer.

1 **Association between the degree of fibrosis in fibrotic**  
2 **focus and the prognosis of breast cancer**

3 Yongfu Li<sup>1</sup>, Yuhan Wei<sup>1</sup>, Wenjun Tang<sup>2</sup>, Jingru Luo<sup>2</sup>, Minghua Wang<sup>3</sup>, Haifeng Lin<sup>2</sup>, Hong  
4 Guo<sup>4</sup>, Yuling Ma<sup>5</sup>, Jun Zhang<sup>6</sup>, Qin Li<sup>1</sup>

5 <sup>1</sup>Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing,  
6 China.

7 <sup>2</sup>Department of Oncology, The Second Affiliated Hospital of Hainan Medical University,  
8 Haikou, Hainan Province, China.

9 <sup>3</sup>Department of Pathology, The Second Affiliated Hospital of Hainan Medical University,  
10 Haikou, Hainan Province, China.

11 <sup>4</sup>Department of Surgery, Beijing Changping District Hospital of Traditional Medicine, Beijing,  
12 China.

13 <sup>5</sup>Department of Gynecology, Beijing Changping District Hospital of Traditional Medicine,  
14 Beijing, China.

15 <sup>6</sup>Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston,  
16 TX, US.

17

18 Corresponding Author:

19 Qin Li

20 No.95, Yongan Road, Xicheng District, Beijing, 100050, China.

21 E-mail address: oncologistinbj@163.com

22

23

24

25

26

27

28

29

30

31

32

33

34

## 35 Abstract

36 **Objective.** To explore the association between the degree of fibrosis in fibrotic focus (FF) and  
37 the prognosis of breast cancer.

38 **Methods.** 169 cases of breast invasive ductal carcinoma (IDC) were included in the study.  
39 Hematoxylin and eosin (H&E) staining was performed in the primary lesion of breast IDC and  
40 the degree of fibrosis in tumor-stromal FF was assessed. The association between the degree of  
41 fibrosis in FF and the well-known clinicopathologic features of breast cancer was investigated  
42 and the influence of the degree of fibrosis in FF on the survival was analyzed.

43 **Results.** Tumor size  $> 2\text{cm}$  ( $P = 0.023$ ), vascular invasion ( $P = 0.011$ ), lymphatic vessel invasion  
44 ( $P < 0.001$ ) and HER-2+ ( $P = 0.032$ ) were positively correlated with the degree of fibrosis in FF  
45 in breast IDC. The result of multivariate analysis showed that lymphatic vessel invasion was the  
46 only independent correlation factor of high fibrosis in FF in breast IDC (OR = 3.82, 95% CI 1.13  
47 ~12.82,  $P = 0.031$ ). The Nottingham prognostic index (NPI) of high fibrosis in FF was  
48 significantly higher than that of mild and moderate fibrosis in FF in the no vascular infiltration  
49 subgroup, the no nerve infiltration subgroup, and the Luminal A subgroup ( $P = 0.014$ , 0.039, and  
50 0.018; respectively).

51 **Conclusions.** The high fibrosis in FF is closely associated with the strong invasiveness and the  
52 high malignancy of breast IDC. The degree of fibrosis in FF might be considered as a very  
53 practical and meaningful pathological feature of breast cancer.

54

## 55 Introduction

56 Breast cancer is the most common female malignant tumor across the world (DeSantis et al.  
57 2017). The prognosis of breast cancer is closely associated with various clinicopathological  
58 characteristics, such as age, tumor size, pathological type, lymph node metastasis status,  
59 histological grade, lymphovascular invasion, Ki-67 index, hormone receptor (HR) status, human  
60 epidermal growth factor receptor-2 (HER-2) expression, etc. These well-known pathological  
61 features have been widely used to make clinical treatment plans and predict the prognosis of  
62 breast cancer. However, the pathophysiology of breast cancer is not only closely related to the  
63 tumor cells, but also related to the tumor microenvironment which is composed of stromal cells,  
64 infiltrating immune cells, vasculature, extracellular matrix, and various cell signaling factors.  
65 Tumor microenvironment plays an important role in the genesis, development, invasion,  
66 metastasis, immune escape and chemotherapy resistance of tumor (Reisfeld 2013). FF is a  
67 pathological change in the tumor microenvironment of breast cancer, with an incidence of 18.7-  
68 53.0% (Colpaert et al. 2001; Hasebe et al. 1996; Kornegoor et al. 2012; Mujtaba et al. 2013; Van

69 den Eynden et al. 2008). Hasebe described the pathologic features of FF in the breast cancer  
70 stroma in detail for the first time: a fibrotic lesion, with an appearance of scar or radiating  
71 expanding fibrosclerotic core, almost located in the center of carcinoma and consisted of  
72 variable amounts of collagen fibers and fibroblasts(Hasebe et al. 1996). At present, it is believed  
73 that the formation of FF is driven mostly by intratumoral hypoxia, which reflects the malignancy  
74 of carcinoma. Thus, FF is considered as a very practical and easily assessable clinicopathological  
75 parameter in breast cancer (Baak et al. 2005; Hasebe et al. 2000; Hasebe et al. 2002; Hasebe et  
76 al. 1997; Maiorano et al. 2010; Van den Eynden et al. 2007). According to the variable  
77 proportions of collagen fibers and fibroblasts, the degree of fibrosis in FF is classified into three  
78 categories: mild, moderate, and high (Hasebe et al. 1996; Van den Eynden et al. 2007). Lots of  
79 research fruits have been presented in the correlation between FF and the poor outcome in breast  
80 cancer. However, little is known about the association between the degree of fibrosis in FF and  
81 the prognosis of breast cancer so far. Whether the degree of fibrosis in FF could better reflect the  
82 prognosis of breast cancer than FF has become a research hotspot. Therefore, a retrospective  
83 study was conducted to explore the association between the degree of fibrosis in FF and the  
84 prognosis of breast cancer.

85

## 86 **Materials and methods**

### 87 *Cases.*

88 The objects of this study were 169 patients with primary breast cancer who underwent surgeries  
89 between January 1, 2016 and December 31, 2018 at the Second Affiliated Hospital of Hainan  
90 Medical University. Inclusion criteria: (1) female diagnosed with primary breast invasive ductal  
91 carcinoma (IDC); (2) IDC must be the principal component (> 50%) in mixed pathological type;  
92 (3) no distant metastasis; (4) no neoadjuvant therapy before surgery; (5) FF stained with H&E  
93 was present in the primary lesion of breast cancer. Exclusion criteria: (1) male breast cancer; (2)  
94 infiltrative specific breast cancer; (3) secondary carcinoma of mammary gland. All included  
95 cases were followed up once every three months by telephone.

### 96 *Ethical.*

97 The Second Affiliated Hospital of Hainan Medical University granted Ethical approval to carry  
98 out the study within its facilities (Ethical Application Ref: LW005). Our Institutional Review  
99 board waived the written consent (The scan of proof was uploaded in the supplemental file).

### 100 *Materials.*

101 Personal information of included cases was collected accurately, including age, family tumor  
102 history, smoking history, and drinking history. The clinicopathological features were evaluated  
103 based on the pathological reports and the medical records, including tumor size, regional lymph

104 node metastasis status, stage, histological grade, vascular invasion, lymphatic vessel invasion,  
105 nervous infiltration, estrogen receptor (ER) status, progesterone receptor (PR) status, ki-67  
106 index, HER-2 expression, etc. The measurement of tumor size was based on the largest diameter  
107 of invasive component in histological sections. The largest diameter of metastatic lesion >  
108 0.2mm in axillary lymph node was defined as regional lymph node metastasis (Plichta et al.  
109 2018). Disease stage was assessed according to the eighth edition of American Joint Committee  
110 on Cancer Staging Manual for breast cancer (Plichta et al. 2018). Histological grade was  
111 evaluated according to Nottingham modification of the Scarff-Bloom-Richardson histological  
112 grading system for invasive breast cancer (Elston & Ellis 1993). Stained with  
113 immunohistochemistry (IHC), the ER expression rate of tumor cells  $\geq 1\%$  was defined as  
114 positive ER expression (ER+), otherwise it was defined as negative ER expression (ER-). This  
115 criterion also was applied to the evaluation of the PR expression (PR+/-). The positive PR  
116 expression was classified into two categories: low ( $< 20\%$ ) and high ( $\geq 20\%$ ) (Prat et al. 2013).  
117 Positive hormone receptor expression (HR+) was defined by ER+ or/and PR+. In the selected  
118 area of slides with  $> 500$  tumor cells, the percentage of tumor cells with positive Ki-67  
119 expression (IHC) was defined as Ki-67 index. Ki-67 index was also classified into two  
120 categories: low ( $\leq 14\%$ ) and high ( $> 14\%$ ) (Goldhirsch et al. 2011). HER-2 expression status was  
121 defined according to the recommendations for HER-2 testing in breast cancer and classified into  
122 two categories: positive (HER-2+) and negative (HER-2-) (Wolff et al. 2013). Combining the  
123 immunohistochemical findings of ER, PR, HER-2, and Ki-67 index, breast cancer was classified  
124 into four molecular subtypes including Luminal A, Luminal B, HER-2 overexpression, and triple  
125 negative breast cancer (TNBC). NPI is a widely accepted clinicopathological scoring system for  
126 early breast cancer prognostication.  $NPI = \text{Tumor size (cm)} \times 0.2 + \text{Histological grade (1-3)} +$   
127  $\text{Lymph node stage (1-3)}$  (Lee & Ellis 2008). Histological grade 1~3 was scored as 1~3 points,  
128 respectively. Lymph node stage 1 meant no node involved. Lymph node stage 2 meant 1~3 low  
129 axillary nodes involved or internal mammary node involved. Lymph node stage 3 meant  $\geq 4$  low  
130 axillary nodes involved and/or the apical axillary nodes involved or both low axillary nodes and  
131 internal mammary nodes involved. Lymph node stage 1~3 was scored as 1~3 points,  
132 respectively.

### 133 *Methods.*

134 All specimens of the primary lesion of breast cancer were fixed in 10% formalin and cut into  
135 5 $\mu\text{m}$ -thick sections which were stained with H&E and analyzed by microscopic examination.  
136 Firstly, the location, size, appearance and components of FF should be observed under low  
137 power microscope. FF was mostly located in the center of the tumor. The size of FF was  $\geq 1$  mm,  
138 otherwise it could not be defined as FF. FF usually appeared as scar-like lesion (*Fig. 1A*) or  
139 irregular moth-eaten radiating fibrosclerotic core (*Fig. 1B*). Numerous tumor cells could be

140 observed frequently around FF. Besides, linear-growing tumor cells and tumor nests could be  
141 usually found in FF with diameter  $> 3\text{mm}$ . Coagulative necrosis could be present in some FFs.  
142 But coagulative necrosis without collagen fiber deposition and fibroblast proliferation was  
143 insufficient to be called FF. Sometimes, haemorrhage could be found in FF. Secondly, the  
144 components of FF were observed under high power microscope. FF was mainly composed of  
145 different proportions of fibroblasts and collagen fibers. The collagen fibers stained with H&E  
146 were thick and arranged closely in bundle. Different amounts of fibroblasts proliferating  
147 abnormally could be found among the collagen fibers. In addition, the densities of micro-vessels  
148 and micro-lymphaticvessels in FF were significantly higher than those in normal tissue.  
149 Evaluating the degree of fibrosis in FF is the last but most important step. According to the  
150 proportion of fibroblasts and collagen fibers, FF was classified into three semi-quantitative  
151 categories (Van den Eynden et al. 2007): (1) mild fibrosis meant that FF consisted of a large  
152 number of fibroblasts and small amount of collagen fibers; (2) moderate fibrosis intermediated  
153 mild fibrosis and high fibrosis; (3) high fibrosis meant that FF was mainly composed of collagen  
154 fibers. Two experienced pathologists were involved in pathological examination and the other  
155 senior pathologist should reassess the degree of fibrosis in FF when the two pathologists did not  
156 agree on the conclusion.

#### 157 *Statistical analysis.*

158 Statistical analyses were performed using IBM SPSS statistics software version 25.0. The mean  
159 age and the mean NPI were described by  $\bar{X}\pm\text{SD}$ . Qualitative data of general and  
160 clinicopathologic features were described by case number, rate, and constituent ratio. Lower  
161 quartile ( $P_{25}$ ), median (M), and upper quartile ( $P_{75}$ ) were used to describe the distribution of NPI  
162 variables in different degrees of fibrosis in FF. The associations between the degree of fibrosis in  
163 FF and clinicopathologic features were analyzed by Mann-whitney U test and Jonckheere-  
164 Terpstra test. After stratificating the patients by clinicopathologic features, most NPI variables  
165 were skewed distribution. So Mann-whitney U test was performed to analyze the difference of  
166 NPI variables between mild and moderate fibrosis in FF and high fibrosis in FF. The factors  
167 significantly associated with the degree of fibrosis in FF in the univariate analyses ( $P < 0.05$ )  
168 were entered together into ordinal logistic regression analysis. The remaining factors in the  
169 multivariate analysis were significant at  $P < 0.05$ . Generalized linear model was used to calculate  
170 the odds ratio (OR) and 95% confidence interval (95% CI). All analyses were two-sided and  $P <$   
171  $0.05$  was considered to indicate a statistically significant difference.

172

## 173 **Results.**

174 *General characteristics of all cases.*

175 Of the 169 cases, the mean age was  $51.6 \pm 10.0$  (range, 28.0-80.0). 6 cases (3.6%) had family  
176 tumor histories, 21 cases (12.4%) had drinking histories, and none had smoking history.

177 *Clinicopathological characteristics of all cases.*

178 The main pathological pattern was IDC. 13 cases (7.7%) were mixed with one kind of infiltrative  
179 specific breast cancers, including mucinous carcinoma (3 cases, 1.8%), lobular carcinoma (2  
180 cases, 0.12%), invasive papillary carcinoma (2 cases, 0.12%), apocrine carcinoma (2 cases,  
181 0.12%), medullary carcinoma (1 case, 0.6%), neuroendocrine carcinoma (1 case, 0.6%),  
182 pleomorphic carcinoma (1 case, 0.6%), and basal carcinoid carcinoma (1 case, 0.6%). Other  
183 clinicopathologic characteristics are presented in *Table 1*.

184 *The degree of fibrosis in FF.*

185 FF had been observed in the primary lesion of each case. 11 cases (6.5%), 65 cases (38.5%), and  
186 93 cases (55.0%) were evaluated as mild, moderate, and high fibrosis, respectively.

187 Representative histology of FF in breast IDC is shown in *Fig. 1C~E*.

188 *Correlation between the clinicopathological characteristics and the degree of fibrosis in FF.*

189 Tumor size > 2cm, vascular invasion, and lymphatic vessel invasion were significantly correlated  
190 with high fibrosis in FF (*Fig. 1F* and *Fig. 2A~C*). Age, lymph node metastasis, stage,  
191 histological grade, and nerve infiltration were not significantly associated with the degree of  
192 fibrosis in FF. Correlation between the clinicopathological characteristics and the degree of  
193 fibrosis in FF is presented in the *Table 2*.

194 *Association between molecular subtypes and degree of fibrosis in FF.*

195 Significant association was observed between HER-2+ and high fibrosis in FF ( $P = 0.032$ ) and  
196 shown in *Fig. 2D* and *Table 3*. The other sub-factors of molecular subtypes (ER, PR, and Ki-67  
197 index) and molecular subtypes were not significantly associated with the degree of fibrosis in FF  
198 (*Table 3*).

199 *Multivariate analysis.*

200 The factors, including tumor size, vascular invasion, lymphatic vessel invasion, and HER-2  
201 expression status, were entered into the ordinal logistical analysis. Due to the missing data of  
202 clinicopathological features, 85 cases (50.3%) were excluded and 84 cases (49.7%) with  
203 complete data were finally included in the ordinal logistic regression analysis. The multivariate  
204 analysis result indicated that lymphatic vessel invasion was the only independent correlated  
205 factor of high fibrosis in FF (OR = 4.10, 95% CI 1.23 ~ 13.70,  $P = 0.021$ ).

206 *Comparison of NPI variables between mild and moderate fibrosis in FF and high fibrosis in FF.*

207 A total of 161 patients with complete data were eligible for NPI scoring. The mean NPI was  
208  $4.60 \pm 1.40$ . Due to the small number of patients (6.5%) with mild fibrosis in FF, we combined the  
209 patients with mild fibrosis and those with moderate fibrosis into one group. Finally, we divided  
210 the 161 cases into two groups, mild and moderate fibrosis group and high fibrosis group. No

211 significant difference was found between the two groups ( $Z = -1.862$ ,  $P = 0.063$ ) (Fig. 3). The  
212 cases were stratificated by the clinicopathological characteristics to further analyze the  
213 differences of NPI variables between mild and moderate fibrosis group and high fibrosis group.  
214 In the no nerve infiltration subgroup, the no vascular infiltration subgroup, and the Luminal A  
215 subgroup, the NPI variables of high fibrosis in FF were significantly higher than those of mild  
216 and moderate fibrosis in FF ( $P = 0.039$ ,  $0.014$ , and  $0.018$ ; respectively) (Table 4 and Fig. 3).  
217

## 218 Discussion

219 Our research found that tumor size  $>2\text{cm}$ , vascular invasion, lymphatic vessel invasion, and  
220 HER-2+ were positively correlated with the degree of fibrosis within FF in breast IDC by  
221 univariate analysis. Moreover, lymphatic vessel invasion was the only independent correlation  
222 factor of high fibrosis in FF in breast IDC by multivariate analysis. Although there was no  
223 significant difference between the NPI of mild and moderate fibrosis in FF and that of high  
224 fibrosis in FF, further analysis showed that the NPI variables of high fibrosis in FF were  
225 significantly higher than those of mild and moderate fibrosis in FF in the no vascular infiltration  
226 subgroup, the no nerve infiltration subgroup, and the Luminal A subgroup. The above results  
227 indicated that the high fibrosis of FF was closely correlated with the aggressive  
228 clinicopathological characteristics of breast IDC and reflected the poor outcome of breast IDC  
229 with no vascular infiltration, no nerve infiltration or Luminal A subtype.

230 Hypoxia is the main cause of the fibrosis in tumor stroma (Daniel et al. 2019; Hoffmann et al.  
231 2018). In hypoxia state, tumor cells secrete platelet derived growth factor (PDGF), transforming  
232 growth factor- $\beta$  (TGF- $\beta$ ), and fibroblast growth factor-2 (FGF-2). All these cell factors act on the  
233 fibroblasts together, resulting in the deposition and remodeling of extracellular matrix and the  
234 graduate formation of FF in the tumor stroma. Besides, PDGF, TGF- $\beta$ , and FGF-2, together with  
235 vascular endothelia growth factor (VEGFR) secreted by fibroblasts and tumor associated  
236 macrophages, promote the angiogenesis, lymphangiogenesis, and lymphovascular invasion  
237 (Shimada et al. 2017; Van den Eynden et al. 2007). The carcinoma-associated fibroblasts  
238 (CAFs), which are the main tumor interstitial cells and transforms from fibroblasts, result in the  
239 deposition of collagen and fibronectin in the extracellular stroma. It is considered that CAFs  
240 play an important function in the formation of FF and are closely related to  
241 the high malignancy of tumor (Balachander et al. 2018; Eiro et al. 2018; Reisfeld 2013; Yang et  
242 al. 2016). In addition, the fibrosis can inhibit T lymphocytes infiltration in tumor stroma and  
243 resist tumor immunity (Salmon et al. 2012). Therefore, FF forming in tumor stroma demonstrates  
244 the high aggressiveness of carcinoma (Van den Eynden et al. 2008). The tumor interstitial  
245 fibrosis associated with the adverse prognosis and anti-tumor drug resistance(Grasso et al. 2017)

246 has been observed in the carcinoma of breast cancer, pancreatic cancer (Thomas &  
247 Radhakrishnan 2019), colorectal cancer(Ikuta et al. 2018), and gastric cancer.

248 Hasebe et al (Hasebe et al. 1996)demonstrated that the histological grade and lymph node  
249 metastasis rate were higher in breast cancer with FF, especially in that with tumor size < 5cm.  
250 Jeong et al (Jeong et al. 2018) revealed that the FF was significantly associated with tumor size >  
251 2cm, lymph node metastasis, poor differentiation, and vascular invasion in breast cancer. The  
252 studies mentioned above had indicated that FF was closely related with the adverse pathological  
253 characteristics of breast cancer. However, previous studies had rarely reported the association  
254 between the degree of fibrosis in FF and the pathological features of breast cancer, so we  
255 conducted this research. Our study found that the degree of fibrosis within FF in breast IDC with  
256 tumor size >2cm was significantly higher than that with tumor size  $\leq$  2cm, indicating the more  
257 severe hypoxia occurred in larger tumors. Besides, our study also revealed that the degree of  
258 fibrosis within FF was significantly higher in breast cancer with vascular infiltration and  
259 lymphatic infiltration. It might be that the densities of blood vessels and lymphatics were higher  
260 in the tumor with high degree fibrosis of FF, increasing the probability of lymphovascular  
261 invasion. The result of multivariate analysis showed that lymphangitic infiltration was the only  
262 independent factor correlating with the high fibrosis in FF in patients with IDC. Due to the  
263 missing data of clinicopathological features, only 49.7% cases with complete data were finally  
264 included in the ordinal logistic regression analysis, which might prevent us from discovering  
265 more factors correlating with the high fibrosis within FF in multivariate analysis. To sum up, the  
266 high fibrosis of FF can predict the strong invasiveness and high malignancy of breast IDC.

267 The relation between FF and the sub-factors of molecular subtypes is not very clear now.  
268 Hasebe et al (Hasebe et al. 2000; Hasebe et al. 1996) showed that FF was significantly correlated  
269 with HER-2 protein overexpression in IDC. Mujtaba et al (Mujtaba et al. 2013) revealed that FF  
270 was negatively associated with HER-2 expression ( $P = 0.021$ ) and Ki-67 index ( $P = 0.001$ ) and  
271 positively associated with HR expression ( $P = 0.007$ ). However, Jeong et al (Jeong et al.  
272 2018)did not find that FF was related to the expression of HR, HER-2, and Ki-67. The results of  
273 the studies above were controversial, which may be caused by the followings. Firstly, there were  
274 other histopathological types of breast cancer besides IDC, which were included in Mujtaba's  
275 and Jeong's studies. And the molecular subtypes of varying histopathological types were distinct  
276 in breast cancer. Moreover, the testing methods and the diagnostic criterion of HER-2 expression  
277 and Ki-67 index were different from the current ones. The association between FF and molecular  
278 subtypes is also unclear. Mujtab et al (Mujtaba et al. 2013) demonstrated that the FF was more  
279 common in Luminal A subtype than in non-Luminal A subtype ( $n = 450$ ,  $P < 0.001$ ). But another  
280 study (Jeong et al. 2018) did not find the association between FF and molecular subtypes ( $n =$   
281  $291$ ,  $P = 0.830$ ). The different conclusions might be due to the inconsistencies of baseline

282 characteristics of the cases included in the two studies. So more studies are needed in exploring  
283 the association between FF and molecular subtypes of breast cancer.

284 Few studies were conducted on the relation between the degree of fibrosis in FF and the sub-  
285 factors of molecular subtypes of breast cancer. Only Hasebe et al (Hasebe et al. 1996) revealed  
286 that the HER-2 protein significantly overexpressed in the breast cancer with moderate and high  
287 fibrosis in FF (90.9% vs. 41.7%,  $n = 153$ ,  $P < 0.02$ ), compared with the breast cancer with mild  
288 fibrosis in FF. The similar conclusion was drawn in our study (97.2% vs. 90.5%,  $n = 131$ ,  $P =$   
289 0.032). Thus it can be seen that moderate and high fibrosis of FF is correlated with the  
290 invasiveness of breast cancer. Our study did not reveal any associations between the degree of  
291 fibrosis and other sub-factors of molecular subtypes including ER, PR and Ki-67 index. In  
292 addition, our result revealed that no association was found between the degree of fibrosis in FF  
293 and molecular subtypes. The relation between the degree of fibrosis in FF and molecular  
294 subtypes was not investigated in previous studies, so more studies are needed to explore the  
295 question.

296 The associations between FF and the survival of breast cancer have been reported in many  
297 studies. Hasebe et al (Hasebe et al. 1998) revealed that the presence of FF predicted higher risk  
298 of recurrence and death in breast cancer with less than four lymph nodes metastases or stage  
299 I ~ II B, compared with the absence of FF. Another study (Colpaert et al. 2001) including 104  
300 cases of breast cancer with stage T1 ~ 2N0M0 showed that the median disease-free survival  
301 (DFS) of cases with the presence of FF was significantly shorter than that with the absence of FF  
302 (25.0 months versus 91.5 months,  $P < 0.05$ ). Shimada et al (Shimada et al. 2017) demonstrated  
303 that the higher risk of recurrence (HR, 7.8; 95%CI: 2.6-22.8;  $P < 0.001$ ) and the shorter median  
304 progression-free survival (PFS) were found in breast cancer with the presence of FF. The studies  
305 above had indicated that the presence of FF was associated with the poor outcome of breast  
306 cancer. Therefore, FF was considered as a significant prognostic feature for breast cancer  
307 (Hasebe et al. 1998; Mujtaba et al. 2013). On the basis of previous studies, we further explored  
308 the correlation between the degree of fibrosis in FF and the long-term survival of breast IDC. All  
309 the cases included in our study had not been followed up to the median survival time. Thus, the  
310 short follow-up period led to the current inability of survival analysis, which was the greatest  
311 deficiency of our study. NPI was adopted as an alternative survival indicator to investigate the  
312 relation between the degree of fibrosis in FF and the long-term survival of breast cancer. NPI,  
313 reported first by Lee et al, is used widely to predict the 10-year overall survival (OS) rate of early  
314 breast cancer (Lee & Ellis 2008). NPI is a scoring system of clinicopathology containing tumor  
315 size, histological grade, and lymph node stage. The NPI scores of 2.02~2.40, 2.41~3.40,  
316 3.41~4.40, 4.41~5.40, 5.41~6.40, and 6.41~6.80 predict the 10-year overall survival rates of

317 96%, 93%, 81%, 74%, 55%, and 38%, respectively. According to the cutoffs of NPI score 3.40  
318 and 5.40, the early breast cancer patients are stratified into good, moderate, and poor groups. The  
319 mean NPI in this study was  $4.60 \pm 1.40$  and most cases were evaluated as moderate prognosis.  
320 Our study revealed that the NPI of high fibrosis in FF showed an upward tendency, compared  
321 with that of mild and moderate fibrosis in FF ( $P = 0.063$ ). Further stratified analysis found that  
322 the NPI of high fibrosis in FF was significantly higher than that of mild and moderate fibrosis in  
323 FF in the no vascular infiltration subgroup, the no nerve infiltration subgroup, and the Luminal A  
324 subgroup. In general, the clinicopathological features of no vascular infiltration, no nerve  
325 infiltration, and Luminal A subtype indicate favorable outcomes of breast IDC. The presence of  
326 FF with high fibrosis could indicate the relatively worse outcomes of cases with the favourable  
327 clinicopathological features of breast IDC mentioned above, which was found in our study. Thus  
328 it can be seen that the degree of fibrosis in FF could be used as a practical and meaningful  
329 pathological feature for predicting the survival outcome of early breast IDC.

330

## 331 **Conclusions**

332 In summary, our study demonstrated that the high fibrosis in FF was closely associated with  
333 the strong invasiveness and the high malignancy of breast IDC. There are some disadvantages in  
334 our study, including the small sample size, partial clinicopathological data missing, and short  
335 follow-up period. In the future study, expanding the sample size, collecting sufficient  
336 clinicopathological data, and extending follow-up time should be considered.

337

## 338 **Acknowledgements**

339 We thank Doctor Rongxin Yan for assistance of collecting pathological data, and thank  
340 Doctor Xiangtao Lin for taking the pathological pictures.

341

## 342 **References**

- 343 Baak JP, Colpaert CG, van Diest PJ, Janssen E, van Diermen B, Albernaz E, Vermeulen PB, and  
344 Van Marck EA. 2005. Multivariate prognostic evaluation of the mitotic activity index and  
345 fibrotic focus in node-negative invasive breast cancers. *Eur J Cancer* 41:2093-2101 DOI:  
346 10.1016/j.ejca.2005.03.038.
- 347 Balachander GM, Talukdar PM, Debnath M, Rangarajan A, and Chatterjee K. 2018.  
348 Inflammatory Role of Cancer-Associated Fibroblasts in Invasive Breast Tumors  
349 Revealed Using a Fibrous Polymer Scaffold. *ACS Appl Mater Interfaces* 10:33814-  
350 33826 DOI: 10.1021/acsami.8b07609.
- 351 Colpaert C, Vermeulen P, van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, and Van

- 352 Marck E. 2001. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an  
353 independent predictor of early distant relapse in lymph node-negative breast cancer  
354 patients. *Histopathology* 39:416-425.
- 355 Daniel SK, Sullivan KM, Labadie KP, and Pillarisetty VG. 2019. Hypoxia as a barrier to  
356 immunotherapy in pancreatic adenocarcinoma. *Clin Transl Med* 8:10 DOI:  
357 10.1186/s40169-019-0226-9.
- 358 DeSantis CE, Ma J, Goding Sauer A, Newman LA, and Jemal A. 2017. Breast cancer statistics,  
359 2017, racial disparity in mortality by state. *CA Cancer J Clin* 67:439-448 DOI:  
360 10.3322/caac.21412.
- 361 Eiro N, Gonzalez L, Martinez-Ordonez A, Fernandez-Garcia B, Gonzalez LO, Cid S,  
362 Dominguez F, Perez-Fernandez R, and Vizoso FJ. 2018. Cancer-associated fibroblasts  
363 affect breast cancer cell gene expression, invasion and angiogenesis. *Cell Oncol (Dordr)*  
364 41:369-378 DOI: 10.1007/s13402-018-0371-y.
- 365 Elston EW, and Ellis IO. 1993. Method for grading breast cancer. *J Clin Pathol* 46:189-190.
- 366 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, and Panel m. 2011.  
367 Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St.  
368 Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer  
369 2011. *Ann Oncol* 22:1736-1747 DOI: 10.1093/annonc/mdr304.
- 370 Grasso C, Jansen G, and Giovannetti E. 2017. Drug resistance in pancreatic cancer: Impact of  
371 altered energy metabolism. *Crit Rev Oncol Hematol* 114:139-152 DOI:  
372 10.1016/j.critrevonc.2017.03.026.
- 373 Hasebe T, Mukai K, Tsuda H, and Ochiai A. 2000. New prognostic histological parameter of  
374 invasive ductal carcinoma of the breast: clinicopathological significance of fibrotic focus.  
375 *Pathol Int* 50:263-272.
- 376 Hasebe T, Sasaki S, Imoto S, Mukai K, Yokose T, and Ochiai A. 2002. Prognostic significance  
377 of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational  
378 study. *Mod Pathol* 15:502-516 DOI: 10.1038/modpathol.3880555.
- 379 Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Iwai M, Imoto S, and Mukai K. 1996. Fibrotic  
380 focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. *Jpn J*  
381 *Cancer Res* 87:385-394.
- 382 Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Tsubono Y, Yamamoto H, and Mukai K. 1998.  
383 Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant  
384 histopathological prognostic parameter for predicting the long-term survival of the  
385 patients. *Breast Cancer Res Treat* 49:195-208.
- 386 Hasebe T, Tsuda H, Tsubono Y, Imoto S, and Mukai K. 1997. Fibrotic focus in invasive ductal  
387 carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence  
388 and tumor death within three years after the initial operation. *Jpn J Cancer Res* 88:590-  
389 599.
- 390 Hoffmann C, Mao X, Brown-Clay J, Moreau F, Al Absi A, Wurzer H, Sousa B, Schmitt F,  
391 Berchem G, Janji B, and Thomas C. 2018. Hypoxia promotes breast cancer cell invasion  
392 through HIF-1alpha-mediated up-regulation of the invadopodial actin bundling protein







- 393 CSRP2. *Sci Rep* 8:10191 DOI: 10.1038/s41598-018-28637-x.
- 394 Ikuta D, Miyake T, Shimizu T, Sonoda H, Mukaisho KI, Tokuda A, Ueki T, Sugihara H, and  
395 Tani M. 2018. Fibrosis in metastatic lymph nodes is clinically correlated to poor  
396 prognosis in colorectal cancer. *Oncotarget* 9:29574-29586 DOI:  
397 10.18632/oncotarget.25636.
- 398 Jeong YJ, Park SH, Mun SH, Kwak SG, Lee SJ, and Oh HK. 2018. Association between lysyl  
399 oxidase and fibrotic focus in relation with inflammation in breast cancer. *Oncol Lett*  
400 15:2431-2440 DOI: 10.3892/ol.2017.7617.
- 401 Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ,  
402 Hinrichs B, and van Diest PJ. 2012. Fibrotic focus and hypoxia in male breast cancer.  
403 *Mod Pathol* 25:1397-1404 DOI: 10.1038/modpathol.2012.101.
- 404 Lee AH, and Ellis IO. 2008. The Nottingham prognostic index for invasive carcinoma of the  
405 breast. *Pathol Oncol Res* 14:113-115 DOI: 10.1007/s12253-008-9067-3.
- 406 Maiorano E, Regan MM, Viale G, Mastropasqua MG, Colleoni M, Castiglione-Gertsch M, Price  
407 KN, Gelber RD, Goldhirsch A, and Coates AS. 2010. Prognostic and predictive impact of  
408 central necrosis and fibrosis in early breast cancer: results from two International Breast  
409 Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. *Breast*  
410 *Cancer Res Treat* 121:211-218 DOI: 10.1007/s10549-009-0360-y.
- 411 Mujtaba SS, Ni YB, Tsang JY, Chan SK, Yamaguchi R, Tanaka M, Tan PH, and Tse GM. 2013.  
412 Fibrotic focus in breast carcinomas: relationship with prognostic parameters and  
413 biomarkers. *Ann Surg Oncol* 20:2842-2849 DOI: 10.1245/s10434-013-2955-0.
- 414 Plichta JK, Ren Y, Thomas SM, Greenup RA, Fayanju OM, Rosenberger LH, Hyslop T, and  
415 Hwang ES. 2018. Implications for Breast Cancer Restaging Based on the 8th Edition  
416 AJCC Staging Manual. *Ann Surg*. DOI: 10.1097/SLA.0000000000003071.
- 417 Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K,  
418 Bernard PS, Nielsen TO, and Perou CM. 2013. Prognostic significance of progesterone  
419 receptor-positive tumor cells within immunohistochemically defined luminal A breast  
420 cancer. *J Clin Oncol* 31:203-209 DOI: 10.1200/JCO.2012.43.4134.
- 421 Reisfeld RA. 2013. The tumor microenvironment: a target for combination therapy of breast  
422 cancer. *Crit Rev Oncog* 18:115-133.
- 423 Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, Mami-  
424 Chouaib F, and Donnadieu E. 2012. Matrix architecture defines the preferential  
425 localization and migration of T cells into the stroma of human lung tumors. *J Clin Invest*  
426 122:899-910 DOI: 10.1172/JCI45817.
- 427 Shimada H, Hasebe T, Sugiyama M, Shibasaki S, Sugitani I, Ueda S, Gotoh Y, Yasuda M, Arai  
428 E, Osaki A, and Saeki T. 2017. Fibrotic focus: An important parameter for accurate  
429 prediction of a high level of tumor-associated macrophage infiltration in invasive ductal  
430 carcinoma of the breast. *Pathol Int* 67:331-341 DOI: 10.1111/pin.12550.
- 431 Thomas D, and Radhakrishnan P. 2019. Tumor-stromal crosstalk in pancreatic cancer and tissue  
432 fibrosis. *Mol Cancer* 18:14 DOI: 10.1186/s12943-018-0927-5.
- 433 Van den Eynden GG, Colpaert CG, Couvelard A, Pezzella F, Dirix LY, Vermeulen PB, Van

- 434 Marck EA, and Hasebe T. 2007. A fibrotic focus is a prognostic factor and a surrogate  
435 marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and  
436 proposal on the criteria of evaluation. *Histopathology* 51:440-451 DOI: 10.1111/j.1365-  
437 2559.2007.02761.x.
- 438 Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van der Auwera I, Bich TX, van  
439 Dam P, den Bakker MA, Dirix LY, Van Marck EA, Vermeulen PB, and Foekens JA.  
440 2008. Gene expression profiles associated with the presence of a fibrotic focus and the  
441 growth pattern in lymph node-negative breast cancer. *Clin Cancer Res* 14:2944-2952  
442 DOI: 10.1158/1078-0432.CCR-07-4397.
- 443 Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC,  
444 Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez  
445 EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical  
446 O, and College of American P. 2013. Recommendations for human epidermal growth  
447 factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College  
448 of American Pathologists clinical practice guideline update. *J Clin Oncol* 31:3997-4013  
449 DOI: 10.1200/JCO.2013.50.9984.
- 450 Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W, Dang Y, Chu Y, Fan J, and He R. 2016. FAP  
451 Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor  
452 Microenvironment via STAT3-CCL2 Signaling. *Cancer Res* 76:4124-4135 DOI:  
453 10.1158/0008-5472.CAN-15-2973.

## Figure 1

Representative histology of fibrotic focus (FF) in breast invasive ductal carcinoma (IDC)


(A) A representative histology of FF with the appearance of scar-like lesion [H&E; magnification,  $\times 20$ ]. (B) A representative histology of FF with the appearance of irregular moth-eaten radiating fibrosclerotic core [H&E; magnification,  $\times 20$ ]. (C) FF with mild fibrosis showing fibroblastic proliferation and small amount of collagen fibers in stroma [H&E; magnification,  $\times 100$ ]. (D) FF with moderate fibrosis intermediating between mild fibrosis and high fibrosis and numerous tumor nests in FF [H&E; magnification,  $\times 100$ ]. (E) FF with high fibrosis showing mostly hyalinized collagen fibers [H&E; magnification,  $\times 100$ ]. (F) High fibrosis and peripheral vascular invasion [H&E; magnification,  $\times 100$ ].



## Figure 2

The distribution of different degrees of fibrosis in FF in different clinicopathologic features.


(A) The comparison of the proportions of different degrees of fibrosis in FF between  $T \leq 2\text{cm}$  ( $T_1$ ) and  $T > 2\text{cm}$  ( $T_{2-3}$ ). (B) The comparison of the proportions of different degrees of fibrosis in FF between VI- and VI+. (C) The comparison of the proportions of different degrees of fibrosis in FF between LVI- and LVI+. (D) The comparison of the proportions of different degrees of fibrosis in FF between HER-2- and HER-2+. Notes: T = tumor size; VI- = no vascular invasion; VI+ = vascular invasion; LVI- = no lymphatic vessel invasion; LVI+ = lymphatic vessel invasion.



## Figure 3

The comparison of NPI variables between mild and moderate fibrosis in FF and high fibrosis in FF.

Notes: VI- = no vascular invasion; NI- = no nervous infiltration.



**Table 1** (on next page)

The characteristics of patients

1 **Table 1:**2 **The characteristics of patients**

<b>Clinicopathologic variables</b>	<b>n (%)</b>	<b>Clinicopathologic variables</b>	<b>n (%)</b>
<b>Age(years)</b>		<b>Nervous infiltration</b>	
≤ 50	79 (46.7)	Yes	32 (18.9)
>50	90 (53.3)	No	81 (47.9)
<b>Tumor size</b>		Unknown	56 (33.2)
≤ 2cm	59 (34.9)	<b>ER</b>	
> 2cm	109 (64.5)	Positive	108 (63.9)
Unknown	1 (0.6)	Negative	60 (35.5)
<b>Lymph node metastasis</b>		Unknown	1 (0.6)
Yes	90 (53.3)	<b>PR</b>	
No	76 (45.0)	Positive	100 (59.1)
Unknown	3 (1.7)	Negative	68 (40.2)
<b>stage</b>		Unknown	1 (0.7)
I	34 (20.1)	<b>Ki-67</b>	
II	87 (51.5)	≤14%	35 (20.7)
III	44 (26.0)	>14%	129 (76.3)
		Unknown	5 (3.0)

3	Unknown	4 (2.4)	<b>Her-2</b>	
4	<b>Histological grade</b>		Positive	36 (21.3)
	I ~ II	88 (52.1)	Negative	95 (56.2)
	III	62 (36.7)	Unknown	38 (22.5)
	Unknown	19 (11.2)	<b>Molecular subtype</b>	
	<b>Vascular invasion</b>		Luminal A	16 (9.5)
	Yes	67 (39.6)	Luminal B	93 (55.0)
	No	60 (35.5)	HER-2	
	Unknown	42 (24.9)	overexpression	17 (10.1)
	<b>Lymphatic vessel invasion</b>		TNBC	24 (14.2)
	Yes	51 (30.1)	Unknown	19 (11.2)
	No	64 (37.9)		
	Unknown	54 (32.0)		

---

**Table 2** (on next page)

The correlation between clinicopathological characteristics and degree of fibrosis in FF

\*Mann-whitney U test # Jonckheere-Terpstra test

1 **Table 2:**2 **The correlation between clinicopathological characteristics and degree of fibrosis in FF**

Clinicopathologic variables	Degree of fibrosis in FF			Z/J- value	P-value
	Mild	Moderate	High		
	n (%)	n (%)	n (%)		
<b>Age (n=169)</b>					
≤50 years	5 (45.5%)	32 (49.2%)	42 (45.2%)	-0.397*	0.691
>50 years	6 (54.5%)	33 (50.8%)	51 (54.8%)		
<b>Tumor size (n=168)</b>					
≤2cm	6 (54.6%)	27 (42.2%)	26 (28.0%)	-2.276*	0.023
>2cm	5 (45.4%)	37 (57.8%)	67 (72.0%)		
<b>Lymph node metastasis (n=166)</b>					
No	6 (54.5%)	34 (53.1%)	36 (39.6%)	-1.746*	0.081
Yes	5 (45.5%)	30 (46.9%)	55 (60.4%)		
<b>stage (n=165)</b>					
I	4 (36.4%)	16 (25.4%)	14 (15.4%)	1.921#	0.055
II	4 (36.4%)	34 (54.0%)	49 (53.8%)		

III	3 (27.2%)	13 (20.6%)	28 (30.8%)		
<b>Histological</b>					
<b>grade (n=150)</b>					
I ~ II	4 (40.0%)	40 (67.8%)	44 (54.3%)	-0.786*	0.432
III	6 (60.0%)	19 (32.2%)	37 (45.6%)		
<b>Vascular</b>					
<b>invasion (n=127)</b>					
No	8 (80.0%)	29 (52.7%)	23 (37.1%)	-2.559*	0.011
Yes	2 (20.0%)	26 (47.3%)	39 (62.9%)		
<b>Lymphatic vessel</b>					
<b>invasion (n=115)</b>					
No	10 (90.9%)	32 (65.3%)	22 (40.0%)	-3.523*	<0.001
Yes	1 (9.1%)	17 (34.7%)	33 (60.0%)		
<b>nervous</b>					
<b>infiltration</b>					
<b>(n=113)</b>					
No	9 (81.8%)	38 (76.0%)	34 (65.4%)	-1.419*	0.156
Yes	2 (18.2%)	12 (24.0%)	18 (34.6%)		

3 \*Mann-whitney U test

4 # Jonckheere-Terpstra test

**Table 3** (on next page)

The association analysis of different variables between molecular subtypes and degree of fibrosis in FF

\*Mann-whitney U test # Jonckheere-Terpstra test

1 **Table 3:**2 **The association analysis of different variables between molecular subtypes and degree of**3 **fibrosis in FF**

Variables	Degree of fibrosis in FF			Z/J- value	P-value
	Mild	Moderate	High		
	n (%)	n (%)	n (%)		
<b>ER (n=168)</b>					
Negative	6 (54.6%)	20 (31.2%)	34 (36.6%)	-0.060*	0.952
Positive	5 (45.4%)	44 (68.8%)	59 (63.4%)		
<b>PR (n=168)</b>					
Negative	7 (63.6%)	22 (34.4%)	39 (41.9%)	-0.040*	0.968
Positive	4 (36.4%)	42 (65.6%)	54 (58.1%)		
<b>Ki-67 (n=164)</b>					
≤14%	3 (27.3%)	16 (26.2%)	16 (17.4%)	-1.377*	0.168
>14%	8 (72.7%)	45 (73.8%)	76 (82.6%)		
<b>HER-2 (n=131)</b>					
Negative	9 (90.0%)	39 (79.6%)	47 (65.3%)	-2.141*	0.032
Positive	1 (10.0%)	10 (20.4%)	25 (34.7%)		
<b>Molecular subtypes</b>					

**(n=150)**

Luminal A	1 (9.1%)	9 (16.7%)	6 (7.1%)	0.572 <sup>#</sup>	0.568
Luminal B	6 (54.5%)	33 (61.1%)	54 (63.5%)		
HER-2 overexpression	0 (0.0%)	2 (3.7%)	15 (17.6%)		
TNBC	4 (36.4%)	10 (18.5%)	10 (11.8%)		

---

4 \*Mann-whitney U test

5 # Jonckheere-Terpstra test

**Table 4**(on next page)

The comparison of NPI variables between mild and moderate fibrosis in FF and high fibrosis in FF after stratification

\*Mann-whitney U test # 5.15 was the median NPI. Since there were only 2 cases, the  $P_{25}$  and  $P_{75}$  could not be calculated.

1 **Table 4:**2 **The comparison of NPI variables between mild and moderate fibrosis in FF and high**3 **fibrosis in FF after stratification**

Stratification	Degree of fibrosis in FF		Z- Value*	P- value
	Mild and moderate	High		
	$P_{25}$ , M, $P_{75}$ (n)	$P_{25}$ , M, $P_{75}$ (n)		
<b>Age (years)</b>				
≤50	3.36,4.50,5.40 (37)	3.36,4.50,5.40 (37)	-0.930	0.352
>50	3.40,4.40,5.20 (36)	4.30,4.70,5.60 (51)	-1.690	0.091
<b>Tumor size</b>				
≤2cm	3.30,4.27,5.20 (32)	3.33,4.26,4.90 (25)	-0.299	0.765
>2cm	3.60,4.60,5.60 (41)	4.50,5.00,5.80 (63)	-1.448	0.148
<b>Lymph node metastasis</b>				
No	3.29,3.50,4.40 (38)	3.30,3.70,4.50 (35)	-0.696	0.486
Yes	4.60,5.36,5.90 (35)	4.60,5.60,6.35 (53)	-1.063	0.288
<b>stage</b>				
I	3.21,3.36,4.29 (20)	3.30,3.40,4.27 (14)	-0.406	0.691
II	3.58,4.50,5.15 (37)	3.70,4.54,5.00 (47)	-0.465	0.642
III	5.32,5.80,6.30 (16)	5.60,6.30,6.80 (27)	-1.436	0.151

**Histological grade**

I ~ II	3.32,3.70,5.00 (43)	3.50,4.50,5.40 (43)	-1.517	0.129
--------	---------------------	---------------------	--------	-------

III	4.50,5.20,5.60 (25)	4.57,5.60,6.45 (37)	-1.443	0.149
-----	---------------------	---------------------	--------	-------

**Vascular invasion**

No	3.31,4.27,4.95 (36)	3.60,5.00,6.35 (21)	-2.458	0.014
----	---------------------	---------------------	--------	-------

Yes	3.58,5.10,5.70 (26)	4.31,4.93,5.85 (38)	-0.616	0.538
-----	---------------------	---------------------	--------	-------

**Lymphatic vessel****invasion**

No	3.36,4.40,5.18 (40)	3.50,5.00,6.00 (21)	-1.709	0.087
----	---------------------	---------------------	--------	-------

Yes	3.58,4.56,5.70 (17)	4.46,5.18,5.80 (32)	-1.441	0.150
-----	---------------------	---------------------	--------	-------

**Nervous infiltration**

No	3.37,4.40,5.20 (45)	3.70,4.80,5.70(32)	-2.063	0.039
----	---------------------	--------------------	--------	-------

Yes	3.35,4.80,5.65 (13)	4.43,5.20,6.53 (16)	-0.430	0.446
-----	---------------------	---------------------	--------	-------

**ER**

Negative	3.68,5.00,5.43 (26)	4.53,5.40,6.30 (32)	-1.799	0.072
----------	---------------------	---------------------	--------	-------

Positive	3.30,4.40,5.00 (47)	3.50,4.47,5.60 (56)	-1.060	0.289
----------	---------------------	---------------------	--------	-------

**PR**

Negative	4.28,4.68,5.39 (28)	4.57,5.10,6.20 (37)	-1.955	0.051
----------	---------------------	---------------------	--------	-------

Positive	3.30,3.90,5.25 (45)	3.40,4.40,5.60 (51)	-0.962	0.336
----------	---------------------	---------------------	--------	-------

**Ki-67**

≤14%	2.77,3.40,4.42 (17)	3.33,3.70,4.58 (16)	-1.353	0.179
>14%	3.65,4.60,5.40 (53)	4.26,4.96,5.70 (71)	-1.519	0.129
<b>HER-2</b>				
Negative	3.39,4.40,5.32 (46)	3.70,4.50,5.70 (43)	-1.450	0.147
Positive	4.56,5.20,5.70 (11)	4.32,5.05,5.80 (24)	-0.124	0.903
<b>Molecular subtypes</b>				
Luminal A	2.37,3.08,3.30 (9)	3.12,4.05,4.45 (6)	-2.359	0.018
Luminal B	3.48,4.58,5.43 (38)	3.70,4.50,5.60 (51)	-0.183	0.855
HER-2 overexpression	5.15 <sup>#</sup> (2)	4.93,5.70,6.58 (14)	-0.954	0.417
TNBC	3.68,4.50,5.40 (14)	4.10,5.00,7.55 (9)	-1.073	0.305

4 \*Mann-whitney U test

5 <sup>#</sup> 5.15 was the median NPI. Since there were only 2 cases, the  $P_{25}$  and  $P_{75}$  could not be calculated.